Gil Aharon Biography and Net Worth

Director of Delcath Systems

Dr. Gilad Aharon is a co-founder and Portfolio Manager at Rosalind Advisors.

Dr. Aharon holds a Ph.D. in Biophysics and Molecular Biology from the University of Toronto. Prior to co-founding Rosalind Advisors, Dr. Aharon worked as an equity analyst at Infinium Securities Inc.

What is Gil Aharon's net worth?: The estimated net worth of Gil Aharon is at least $10.72 million as of March 19th, 2024. Dr. Aharon owns 1,069,710 shares of Delcath Systems stock worth more than $10,718,494 as of December 5th. This net worth approximation does not reflect any other assets that Dr. Aharon may own. Learn More about Gil Aharon's net worth.
How do I contact Gil Aharon?: The corporate mailing address for Dr. Aharon and other Delcath Systems executives is 1633 BROADWAY SUITE 22C, NEW YORK NY, 10019. Delcath Systems can also be reached via phone at 212-489-2100 and via email at [email protected]. Learn More on Gil Aharon's contact information.
Has Gil Aharon been buying or selling shares of Delcath Systems?: Gil Aharon has not been actively trading shares of Delcath Systems during the last quarter. Most recently, on Tuesday, March 19th, Gil Aharon bought 26,882 shares of Delcath Systems stock. The stock was acquired at an average cost of $3.72 per share, with a total value of $100,001.04. Following the completion of the transaction, the director now directly owns 1,069,710 shares of the company's stock, valued at $3,979,321.20. Learn More on Gil Aharon's trading history.
Who are Delcath Systems' active insiders?: Delcath Systems' insider roster includes Gil Aharon (Director), Gerard Michel (CEO), Sandra Pennell (SVP), John Purpura (COO), Steven Salamon (Director), John Sylvester (Director), and Vojo Vukovic (Chief Medical Officer). Learn More on Delcath Systems' active insiders.
Are insiders buying or selling shares of Delcath Systems?: During the last twelve months, Delcath Systems insiders bought shares 1 times. They purchased a total of 11,500 shares worth more than $98,095.00. The most recent insider tranaction occured on November, 11th when CEO Gerard J Michel bought 11,500 shares worth more than $98,095.00. Insiders at Delcath Systems own 17.4% of the company. Learn More about insider trades at Delcath Systems.
Information on this page was last updated on 11/11/2025.

Gil Aharon Insider Trading History at Delcath Systems

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/19/2024	Buy	26,882	$3.72	$100,001.04	1,069,710
11/16/2020	Buy	2,000	$12.00	$24,000.00

Gil Aharon Buying and Selling Activity at Delcath Systems

Delcath Systems Company Overview

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

Today's Range

Now: $10.02

$9.57

$10.12

50 Day Range

MA: $9.94

$8.19

$12.36

2 Week Range

Now: $10.02

$8.12

$18.23

Volume

605,955 shs

Average Volume

796,411 shs

Market Capitalization

$353.81 million

P/E Ratio

1,002.00

Dividend Yield

N/A

Beta

0.41